Member of board of directors of Exor N.V. and Solvay S.A.
Member of the supervisory board of Randstad N.V.
of the board of directors of HEC Paris Business School and Kite
Insights Limited (the Climate School).
Group chief financial officer, executive board member, of
Heineken N.V, 2015-2021.
Group chief financial officer,
executive board member, at JCDecaux SA, 2010-2015.
strategic officer, chief financial officer and deputy chief
financial officer at Sanofi Aventis SA, 1996-2010.
Considered independent under the Danish Corporate Governance
Member of the Board of Directors since March
2019. Most recently elected in March 2023 for a term of one
Member of the Audit Committee since March 2019 and
chair of the Committee since March 2021. The Board has designated Ms
Debroux as financial expert as defined by the US Securities and
Exchange Commission (SEC) and assessed that Ms Debroux qualifies as
independent pursuant to the US Securities Exchange Act. The Board
assessed that Ms Debroux has competences in accounting and auditing
as required by the Danish Act on Approved Auditors and Audit
Member of the Remuneration Committee since March
Global corporate leadership.
Healthcare and pharma
Finance & accounting.
development, M&A and external innovation sourcing.
Human capital management.
Environmental, social and
1992: Master Degree, HEC Paris, Ecoles des Hautes Etudes
French, born 1969. Female.
NOVO NORDISK HQ
Novo Nordisk A/S Novo Alle 1 2880 Bagsværd
Denmark +45-4444-8888 CVR-no. 24256790
Our medicines are for the approved indication for which they are
authorised in the local country or region. For more information,
please visit ourproduct page